May 10, 2017 9:36am EDT Sapience Therapeutics Adds Biotech Veteran, Christian S. Schade, to Board of Directors
Mar 29, 2017 9:36am EDT Sapience Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ST-36 for the Treatment of Glioma
Sep 07, 2016 9:36am EDT Sapience Therapeutics Adds Former Head of the National Cancer Institute, Samuel Broder, MD, to Board of Directors
Jul 20, 2016 9:36am EDT Sapience Therapeutics, Inc. Enters Into Exclusive License Agreement With Columbia University for Novel Cancer Treatment
